Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 26, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 26, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg".